Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rockwell Medical (RMTI) EBITDA Margin (2016 - 2025)

Rockwell Medical (RMTI) has disclosed EBITDA Margin for 16 consecutive years, with 9.95% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin fell 1678.0% year-over-year to 9.95%, compared with a TTM value of 6.37% through Sep 2025, down 695.0%, and an annual FY2024 reading of 0.6%, up 858.0% over the prior year.
  • EBITDA Margin was 9.95% for Q3 2025 at Rockwell Medical, down from 8.39% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 6.84% in Q3 2024 and bottomed at 54.52% in Q4 2021.
  • Average EBITDA Margin over 5 years is 18.39%, with a median of 9.95% recorded in 2025.
  • The sharpest move saw EBITDA Margin soared 4435bps in 2022, then crashed -1678bps in 2025.
  • Year by year, EBITDA Margin stood at 54.52% in 2021, then surged by 81bps to 10.17% in 2022, then soared by 76bps to 2.48% in 2023, then rose by 15bps to 2.1% in 2024, then tumbled by -373bps to 9.95% in 2025.
  • Business Quant data shows EBITDA Margin for RMTI at 9.95% in Q3 2025, 8.39% in Q2 2025, and 7.19% in Q1 2025.